Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children <5 years old: 2006-2019.
Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children <5 years old: 2006-2019.
复制标题
轮状病毒疫苗接种对 5 岁以下儿童腹泻住院和死亡的全球影响：2006-2019 年。
DOI：
--
复制
发表时间：
2020
影响因子：
6.4
通讯作者：
J. Tate
中科院分区：
文献类型：
--
作者：
Eleanor M. Burnett;U. Parashar;J. Tate
自2006年以来，已有100多个国家将轮状病毒疫苗纳入其免疫规划。我们回顾了已发表的关于5岁以下儿童轮状病毒住院、急性胃肠炎（AGE）住院和AGE死亡相对减少的数据。纳入了2006年1月1日至2019年12月31日期间发表的文章，其中包含轮状病毒疫苗引入前后至少12个月的数据。相对减少被抽象成一个标准化的形式。描述性统计量表示为中位数和四分位距（IQR）。我们共审查了1827条记录，包括来自49个国家的105篇文章。在<5岁的儿童中，轮状病毒住院率中位数降低59%（IQR：46，74），AGE住院率中位数降低36%（IQR：23，47），AGE死亡率中位数降低36%（IQR：28，46）。在儿童死亡率低的国家，在较年轻的年龄组和覆盖率较高的国家，下降幅度较大。在引入轮状病毒疫苗前，因腹泻住院的<5岁儿童中轮状病毒检测阳性标本的中位百分比为40%（IQR：28，45），引入后4年为20%（IQR：20，20）。总体而言，我们发现轮状病毒和AGE住院和死亡的持续影响。这些结果应该鼓励仍在考虑实施轮状病毒疫苗的国家。
Since 2006, more than 100 countries have introduced rotavirus vaccine into their immunization programs. We reviewed published data on relative reductions of rotavirus hospitalizations, acute gastroenteritis (AGE) hospitalizations, and AGE deaths among children <5 years old. Articles published from 1 January 2006 to 31 December 2019 with at least 12 months of data before and after rotavirus vaccine introduction were included. Relative reductions were abstracted into a standardized form. Descriptive statistics are presented as medians and interquartile ranges (IQR). We reviewed 1827 total records and included 105 articles from 49 countries. Among children <5 years old, there was a median reduction of 59% (IQR: 46, 74) in rotavirus hospitalizations, 36% (IQR: 23, 47) in AGE hospitalizations, and 36% (IQR: 28, 46) AGE mortality. Reductions were larger in countries with low child mortality, among younger age groups, and in countries with higher coverage. The median percentage of specimens that tested positive for rotavirus among children <5 years old hospitalized for diarrhea was 40% (IQR: 28, 45) before rotavirus vaccine introduction and 20% (IQR: 20, 20) 4 years after introduction. Overall, we found sustained impact on rotavirus and AGE hospitalizations and deaths. These results should encourage countries still considering rotavirus vaccine implementation.